Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2006 4
2007 7
2008 6
2009 3
2010 5
2011 12
2012 18
2013 9
2014 13
2015 15
2016 22
2017 21
2018 29
2019 46
2020 49
2021 39
2022 45
2023 51
2024 27

Text availability

Article attribute

Article type

Publication date

Search Results

378 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for sun ying huang
Search for Shun-Ying Huang instead (1 results)
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma.
Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, Jin F, Shi M, Chen YP, Hu WH, Cheng ZB, Wang SY, Tian Y, Wang XC, Sun Y, Li JG, Li WF, Li YH, Tang LL, Mao YP, Zhou GQ, Sun R, Liu X, Guo R, Long GX, Liang SQ, Li L, Huang J, Long JH, Zang J, Liu QD, Zou L, Su QF, Zheng BM, Xiao Y, Guo Y, Han F, Mo HY, Lv JW, Du XJ, Xu C, Liu N, Li YQ, Chua MLK, Xie FY, Sun Y, Ma J. Zhang Y, et al. Among authors: sun y. N Engl J Med. 2019 Sep 19;381(12):1124-1135. doi: 10.1056/NEJMoa1905287. Epub 2019 May 31. N Engl J Med. 2019. PMID: 31150573 Clinical Trial.
ENO1 and Cancer.
Huang CK, Sun Y, Lv L, Ping Y. Huang CK, et al. Among authors: sun y. Mol Ther Oncolytics. 2022 Jan 3;24:288-298. doi: 10.1016/j.omto.2021.12.026. eCollection 2022 Mar 17. Mol Ther Oncolytics. 2022. PMID: 35434271 Free PMC article. Review.
The tumor immune microenvironment of nasopharyngeal carcinoma after gemcitabine plus cisplatin treatment.
Lv J, Wei Y, Yin JH, Chen YP, Zhou GQ, Wei C, Liang XY, Zhang Y, Zhang CJ, He SW, He QM, Huang ZL, Guan JL, Shen JY, Li XM, Li JY, Li WF, Tang LL, Mao YP, Guo R, Sun R, Zheng YH, Zhou WW, Xiong KX, Wang SQ, Jin X, Liu N, Li GB, Kuang DM, Sun Y, Ma J. Lv J, et al. Among authors: sun y. Nat Med. 2023 Jun;29(6):1424-1436. doi: 10.1038/s41591-023-02369-6. Epub 2023 Jun 6. Nat Med. 2023. PMID: 37280275
Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial.
Tang LL, Guo R, Zhang N, Deng B, Chen L, Cheng ZB, Huang J, Hu WH, Huang SH, Luo WJ, Liang JH, Zheng YM, Zhang F, Mao YP, Li WF, Zhou GQ, Liu X, Chen YP, Xu C, Lin L, Liu Q, Du XJ, Zhang Y, Sun Y, Ma J. Tang LL, et al. Among authors: sun y. JAMA. 2022 Aug 23;328(8):728-736. doi: 10.1001/jama.2022.13997. JAMA. 2022. PMID: 35997729 Free PMC article. Clinical Trial.
CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes.
Liang P, Xu Y, Zhang X, Ding C, Huang R, Zhang Z, Lv J, Xie X, Chen Y, Li Y, Sun Y, Bai Y, Songyang Z, Ma W, Zhou C, Huang J. Liang P, et al. Among authors: sun y. Protein Cell. 2015 May;6(5):363-372. doi: 10.1007/s13238-015-0153-5. Epub 2015 Apr 18. Protein Cell. 2015. PMID: 25894090 Free PMC article.
Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.
Chen YP, Liu X, Zhou Q, Yang KY, Jin F, Zhu XD, Shi M, Hu GQ, Hu WH, Sun Y, Wu HF, Wu H, Lin Q, Wang H, Tian Y, Zhang N, Wang XC, Shen LF, Liu ZZ, Huang J, Luo XL, Li L, Zang J, Mei Q, Zheng BM, Yue D, Xu J, Wu SG, Shi YX, Mao YP, Chen L, Li WF, Zhou GQ, Sun R, Guo R, Zhang Y, Xu C, Lv JW, Guo Y, Feng HX, Tang LL, Xie FY, Sun Y, Ma J. Chen YP, et al. Among authors: sun y. Lancet. 2021 Jul 24;398(10297):303-313. doi: 10.1016/S0140-6736(21)01123-5. Epub 2021 Jun 7. Lancet. 2021. PMID: 34111416 Clinical Trial.
Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III Trial.
Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, Jin F, Shi M, Chen YP, Hu WH, Cheng ZB, Wang SY, Tian Y, Wang XC, Sun Y, Li JG, Li WF, Li YH, Mao YP, Zhou GQ, Sun R, Liu X, Guo R, Long GX, Liang SQ, Li L, Huang J, Long JH, Zang J, Liu QD, Zou L, Su QF, Zheng BM, Xiao Y, Guo Y, Han F, Mo HY, Lv JW, Du XJ, Xu C, Liu N, Li YQ, Xie FY, Sun Y, Ma J, Tang LL. Zhang Y, et al. Among authors: sun y. J Clin Oncol. 2022 Aug 1;40(22):2420-2425. doi: 10.1200/JCO.22.00327. Epub 2022 Jun 16. J Clin Oncol. 2022. PMID: 35709465 Clinical Trial.
378 results